Galecto is developing GB2064 as a potential treatment for myelofibrosis, a fibrosis-related blood cancer. LOXL2 is involved in the formation of the extracellular matrix contributing to the fibrotic progression. GB2064 has demonstrated inhibition of LOXL2 activity in cell-based assays and preclinical models.
Myelofibrosis is a type of bone marrow cancer that causes scarring in the bone marrow, and disrupts the body’s normal production of blood cells, which leads to multiple negative impacts: thrombocytopenia, or greater incidence of low platelet counts; anemia, or low red blood cell counts; and a greater need for red-blood-cell transfusions. It is associated with significantly reduced quality of life and median survival is less than three years.
Galecto also focuses on cancers where galectin expression and activity has been associated with the development and progression of tumors, often with a poor prognosis. In particular, galectins may determine the ability of cancer cells to evade the immune system.
Galecto, Inc. develops small molecules for the treatment of severe diseases, including fibrosis and cancer. The company, founded in 2011, builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform.